R3767-ONC-22122 Phase 3 study of fixed dose combinations of fianlimab and cemiplimab vs relatlimab and nivolumab in participants with unresectable or metastatic melanoma by Mary Beth Wilwerding | Aug 19, 2026
VMT01-T101 Phase 1/2a, First-in-human, Multicenter Dose Escalation and Dose Expansion Study of [203/212Pb] VMT01 Recepto-targeted, Image-guided Alpha-particle Therapy in Patients with Previously Treated unresectable or metastatic Melanoma by Mary Beth Wilwerding | Aug 19, 2026
